TARPLIN, DOWNS & YOUNG, LLC

Lobbying for SAREPTA THERAPEUTICS · A biopharmaceutical company focused on innovative RNA-based therapeutics

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · Massachusetts · House · Senate · $90,000.00 income · posted Jan 20, 2026

Lobbying activity 3

Budget/Appropriations

federal budget issues

Health Issues

innovation, Duchenne Muscular Dystrophy, platform technologies, value based contracting, gene therapy

Medicare/Medicaid

Medicaid drug rebate program, coverage, state program operations, waivers, gene therapy, value based contracting, Medicaid value based payment rule

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.